About Arcturus Therapeutics
Arcturus Therapeutics is a company based in San Diego (United States) founded in 2013. Arcturus Therapeutics has raised $1.3 million across 7 funding rounds from investors including Cystic Fibrosis Foundation. The company has 176 employees as of December 31, 2024. Arcturus Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and Rhythm Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Employees 176 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arcturus Therapeutics Holdings Inc.
-
Annual Revenue
$138.39 M (USD)-12.27as on Dec 31, 2024
-
Net Profit
-$80.94 M (USD)-172.3as on Dec 31, 2024
-
EBITDA
-$35.58 M (USD)-2877.57as on Dec 31, 2024
-
Total Equity Funding
$1.3 M (USD)
in 7 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
176
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arcturus Therapeutics
Arcturus Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ARCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Arcturus Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Arcturus Therapeutics
Arcturus Therapeutics has successfully raised a total of $1.3M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arcturus Therapeutics
Arcturus Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cystic Fibrosis Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research funding and support for cystic fibrosis patients are provided.
|
Locked | Locked | Locked |
Investor details for Arcturus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arcturus Therapeutics
Investment portfolio details for Arcturus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arcturus Therapeutics
Detailed financials for Arcturus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arcturus Therapeutics Comparisons
Peer comparison for Arcturus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arcturus Therapeutics
Arcturus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Arcturus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arcturus Therapeutics
Complete news archive for Arcturus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arcturus Therapeutics
Arcturus Therapeutics was founded in 2013.
Arcturus Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Arcturus Therapeutics is a funded company, having raised a total of $1.3M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Arcturus Therapeutics is 176.
Annual revenue of Arcturus Therapeutics is $138.39M as on Dec 31, 2024.
Arcturus Therapeutics was founded in 2013 and is based in San Diego, United States. RNAi technologies are developed for addressing rare orphan diseases within the biotechnology sector. Proprietary LUNAR lipid-mediated delivery and STARR mRNA Technology are applied to create RNA medicines targeting rare and infectious diseases. The lead candidate, LUNAR-OTC, is directed toward ornithine transcarbamylase deficiency.
Arcturus Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Arcturus Therapeutics is publicly traded on NASDAQ under the ticker symbol ARCT.
Arcturus Therapeutics has 1 investor. Key investors include Cystic Fibrosis Foundation.
The ticker symbol of Arcturus Therapeutics is ARCT on NASDAQ.